Bone Biologics Corporation Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 08/09/2024 | Q2 2024 | -$0.67 | $0 | |||
| 05/14/2024 | Q1 2024 | -$1.31 | $0 | |||
| 02/21/2024 | Q4 2023 | -$2.90 | $0 | |||
| 11/14/2023 | Q3 2023 | -$4.90 | $0 | |||
| 08/14/2023 | Q2 2023 | -$13.52 | $0 | |||
| 05/15/2023 | Q1 2023 | -$63.62 | $0 | |||
| 11/20/2023 | Q4 2022 | $48.19 | $0 | |||
| 11/14/2022 | Q3 2022 | -$3.53 | $0 | |||
| 08/11/2022 | Q2 2022 | -$0.05 | $0 | |||
| 05/13/2022 | Q1 2022 | -$2.00 | $0 | |||
| 03/15/2022 | Q4 2021 | -$0.52 | $0 | |||
| 11/15/2021 | Q3 2021 | -$5.25 | $0 | |||
| 08/16/2021 | Q2 2021 | -$5.07 | $0 | |||
| 05/21/2021 | Q1 2021 | -$4.45 | $0 | |||
| 04/15/2021 | Q4 2020 | -$4.68 | $0 | |||
| 04/15/2021 | Q3 2020 | -$4.06 | $0 | |||
| 04/15/2021 | Q2 2020 | -$3.92 | $0 | |||
| 04/15/2021 | Q1 2020 | -$6.15 | $0 | |||
| 03/27/2020 | Q4 2019 | -$5.47 | $0 | |||
| 11/14/2019 | Q3 2019 | -$5.77 | $0 |
Bone Biologics Corporation Earnings: Frequently Asked Questions
-
When is Bone Biologics Corporation's earnings date?
Bone Biologics Corporation has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 30th, 2023 based off last year's report dates.
-
How can I listen to Bone Biologics Corporation's earnings conference call?
The conference call for Bone Biologics Corporation's latest earnings report can be listened to online.
-
How can I read Bone Biologics Corporation's conference call transcript?
The conference call transcript for Bone Biologics Corporation's latest earnings report can be read online.
-
How much profit does Bone Biologics Corporation generate each year?
Bone Biologics Corporation (:BBLGW) has a recorded net income of $0. Bone Biologics Corporation has generated $-34.03 earnings per share over the last four quarters.
-
What is Bone Biologics Corporation's price-to-earnings ratio?
Bone Biologics Corporation (:BBLGW) has a price-to-earnings ratio of -0.38 and price/earnings-to-growth ratio is -0.01.
